[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112017015452A2 - formulação farmacêutica - Google Patents

formulação farmacêutica

Info

Publication number
BR112017015452A2
BR112017015452A2 BR112017015452-8A BR112017015452A BR112017015452A2 BR 112017015452 A2 BR112017015452 A2 BR 112017015452A2 BR 112017015452 A BR112017015452 A BR 112017015452A BR 112017015452 A2 BR112017015452 A2 BR 112017015452A2
Authority
BR
Brazil
Prior art keywords
injection
pharmaceutical formulation
pharmaceutical compositions
corticosteroid
disclosed
Prior art date
Application number
BR112017015452-8A
Other languages
English (en)
Other versions
BR112017015452B1 (pt
Inventor
Shah
G. Mahendra
Original Assignee
Semnur Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semnur Pharmaceuticals, Inc. filed Critical Semnur Pharmaceuticals, Inc.
Publication of BR112017015452A2 publication Critical patent/BR112017015452A2/pt
Publication of BR112017015452B1 publication Critical patent/BR112017015452B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)

Abstract

são divulgadas composições farmacêuticas aquosas que fornecem liberação controlada de compostos corticosteroides. a composição farmacêutica compreende um corticosteroide solúvel e pelo menos um agente de aumento de viscosidade. também são fornecidos métodos para uso nas composições farmacêuticas em uma injeção epidural, injeção intra-articular ou injeção intralesional.
BR112017015452-8A 2015-01-21 2016-01-20 Formulação farmacêutica BR112017015452B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562106045P 2015-01-21 2015-01-21
US62/106,045 2015-01-21
PCT/US2016/014165 WO2016118649A1 (en) 2015-01-21 2016-01-20 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
BR112017015452A2 true BR112017015452A2 (pt) 2018-01-23
BR112017015452B1 BR112017015452B1 (pt) 2022-11-08

Family

ID=55405453

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015452-8A BR112017015452B1 (pt) 2015-01-21 2016-01-20 Formulação farmacêutica

Country Status (14)

Country Link
US (4) US10500284B2 (pt)
EP (2) EP3925597A1 (pt)
JP (4) JP6829201B2 (pt)
KR (2) KR20230157534A (pt)
CN (2) CN112957320A (pt)
AU (1) AU2016209332B2 (pt)
BR (1) BR112017015452B1 (pt)
CA (1) CA2974657C (pt)
ES (1) ES2877371T7 (pt)
HK (2) HK1243932A1 (pt)
IL (1) IL253570B (pt)
MX (2) MX2017009482A (pt)
TW (3) TWI674899B (pt)
WO (1) WO2016118649A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9833460B2 (en) 2013-01-23 2017-12-05 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation
TWI674899B (zh) 2015-01-21 2019-10-21 美商桑紐爾製藥公司 醫藥配方
EP3302491A4 (en) * 2015-06-02 2019-02-27 NewSouth Innovations Pty Limited FORMULATION AND METHOD FOR LIMITING NERVENTRAUMA
SG11202100054YA (en) 2018-07-09 2021-02-25 Taiwan Liposome Co Ltd Methods to reduce complications of intra-articular steroid
IT201800010415A1 (it) * 2018-11-19 2020-05-19 Innate S R L Composizione iniettabile comprendente acido ialuronico e trealosio e uso della detta composizione.
CN112870155B (zh) * 2021-03-08 2023-06-30 上海昱聚科技有限公司 缓释地塞米松药物的凝胶注射剂及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL25251A (en) * 1965-07-20 1969-11-12 Merck & Co Inc Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation
US3962430A (en) 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
FI105075B (fi) 1996-01-10 2000-06-15 Suprakort Oy Kombinaatioinjektiovalmisteen käyttö
IT1288290B1 (it) * 1996-06-21 1998-09-11 Fidia Spa In Amministrazione S Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
JPH11279065A (ja) * 1998-03-25 1999-10-12 Shiseido Co Ltd 局所投与炎症治療剤
US6921532B1 (en) 2000-06-22 2005-07-26 Spinal Restoration, Inc. Biological Bioadhesive composition and methods of preparation and use
US6747090B2 (en) 2001-07-16 2004-06-08 Pharmacia Groningen Bv Compositions capable of forming hydrogels in the eye
US20040006052A1 (en) 2002-04-15 2004-01-08 Gudas Charles J. Injection solutions to treat neuropathic symptoms and other sensorimotor disorders that are due to neuromas of the foot or other entrapment neuropathies of peripheral nerves, and method of use
CN101094690A (zh) * 2003-11-12 2007-12-26 阿勒根公司 用于治疗眼后节的组合物及方法
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050186229A1 (en) 2004-02-24 2005-08-25 Emmett Clemente Pleasant-tasting aqueous liquid composition of prednisolone sodium phosphate
JP2007001926A (ja) * 2005-06-24 2007-01-11 Ltt Bio-Pharma Co Ltd 吸入・噴霧用ステロイド製剤
JP4969812B2 (ja) * 2005-07-22 2012-07-04 久光製薬株式会社 ハイドロゲル組成物
US20070099882A1 (en) 2005-10-27 2007-05-03 Gurney Harry C Methods and compositions for prolonged alleviation of articular joint pain
CA2633957A1 (en) 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
CN100534434C (zh) 2006-05-15 2009-09-02 西安力邦制药有限公司 透明质酸钠地塞米松脂肪乳制剂及其应用
WO2008057364A1 (en) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Method for treating blepharitis
US20080317805A1 (en) 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US9421356B2 (en) 2007-08-28 2016-08-23 Teikoku Pharma Usa, Inc. Transdermal methods and systems for the delivery of corticosteroid compounds
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US20090143807A1 (en) 2007-12-03 2009-06-04 Vertos Medical, Inc., A Delaware Corporation Percutaneous Devices for Separating Tissue, Kits and Methods of Using the Same
JP2011513337A (ja) 2008-04-18 2011-04-28 ウォーソー・オーソペディック・インコーポレーテッド 椎間板ヘルニアを治療するための方法および組成物
CN103417472B (zh) 2008-05-14 2018-01-02 奥德纳米有限公司 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
CN101683532A (zh) * 2008-09-25 2010-03-31 武汉诺安药业有限公司 含玻璃酸或其盐的眼用复方药物制剂
US20110281834A1 (en) 2008-11-10 2011-11-17 Friden Phillip M Pharmaceutical Formulations for Iontophoretic Delivery of a Corticosteroid
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
RU2459615C1 (ru) 2011-03-05 2012-08-27 Илья Александрович Марков Глазные капли для лечения болезни сухого глаза
WO2013085769A1 (en) 2011-12-06 2013-06-13 Alcon Research, Ltd. Cellulosic gel composition with improved viscosity stability
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
US9833460B2 (en) 2013-01-23 2017-12-05 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation
TWI674899B (zh) * 2015-01-21 2019-10-21 美商桑紐爾製藥公司 醫藥配方

Also Published As

Publication number Publication date
KR20170103974A (ko) 2017-09-13
IL253570A0 (en) 2017-09-28
JP2021183649A (ja) 2021-12-02
WO2016118649A1 (en) 2016-07-28
US20200197523A1 (en) 2020-06-25
IL253570B (en) 2020-08-31
ES2877371T3 (es) 2021-11-16
HK1243932A1 (zh) 2018-07-27
US11020485B2 (en) 2021-06-01
TW201630609A (zh) 2016-09-01
MX2021012029A (es) 2021-10-26
KR20230157534A (ko) 2023-11-16
HK1245653A1 (zh) 2018-08-31
CA2974657A1 (en) 2016-07-28
CN107205926A (zh) 2017-09-26
US20210386859A1 (en) 2021-12-16
EP3925597A1 (en) 2021-12-22
CN112957320A (zh) 2021-06-15
US20180185494A1 (en) 2018-07-05
TW202005652A (zh) 2020-02-01
JP6829201B2 (ja) 2021-02-10
JP2020073576A (ja) 2020-05-14
JP2018502872A (ja) 2018-02-01
US10500284B2 (en) 2019-12-10
BR112017015452B1 (pt) 2022-11-08
JP7269992B2 (ja) 2023-05-09
EP3247329B1 (en) 2021-05-19
CA2974657C (en) 2024-02-20
EP3247329A1 (en) 2017-11-29
TWI674899B (zh) 2019-10-21
EP3247329B3 (en) 2022-02-09
US10117938B2 (en) 2018-11-06
TW202245791A (zh) 2022-12-01
KR102600792B1 (ko) 2023-11-10
JP2021143209A (ja) 2021-09-24
US20180008714A1 (en) 2018-01-11
CN107205926B (zh) 2021-03-05
TWI772659B (zh) 2022-08-01
JP7065129B2 (ja) 2022-05-11
MX2017009482A (es) 2017-11-15
ES2877371T7 (es) 2022-05-24
AU2016209332B2 (en) 2020-10-22
TWI845973B (zh) 2024-06-21
AU2016209332A1 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
BR112017015452A2 (pt) formulação farmacêutica
BR112018010720A2 (pt) agonistas do receptor de apelina e métodos de uso
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2022003572A (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
BR112014017716A8 (pt) composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112016002233A2 (pt) composições de adoçante
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112017019352A2 (pt) composições tópicas comprimidas a corticosteróide aplicações relacionadas
BR112017001339A2 (pt) método, pasta de cimento e sistema
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
BR112015006727A2 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BR112017000462A2 (pt) detergente para lavar louça de pastilha e métodos para a fabricação e uso do mesmo
BR112017001888A2 (pt) formulações biológicas para instilação intravesical
BR112018069115A2 (pt) composições, composições de revestimento aquosas e métodos para melhorar a estabilidade de congelamento/descongelamento de composições de revestimento aquosas
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
CL2018002200A1 (es) Administración combinada de un agente de penetración y un compuesto de azufre que contiene compuesto para las plantas.
BR112015022475A8 (pt) formulação líquida e método para impedir a oxidação de uma proteína em uma formulação de proteína

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25G Requested change of headquarter approved

Owner name: SEMNUR PHARMACEUTICALS, INC. (US)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/01/2016, OBSERVADAS AS CONDICOES LEGAIS